Last 48 quarters of trend data · Healthcare · Immunology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -34.85 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 99.80 | — | — | — | 6.80 | — | — | — | — | — | — | — | — | — | 15.67 | 34.52 | 43.76 | 71.19 | 16.61 | 27.86 | 16.08 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | -5.7% | +23.9% | +172.1% | -23.8% | +99.2% | — | — | |
| P/B Ratio | 9.31 | 7.49 | 6.83 | 5.91 | 3.44 | 2.22 | 1.99 | 2.02 | 2.11 | 4.57 | 2.85 | 9.10 | 2.54 | — | — | 0.81 | 0.58 | 0.73 | 0.49 | 2.46 | 2.79 |
| — | +236.4% | +242.7% | +193.0% | +62.7% | -51.3% | -29.9% | -77.8% | -16.7% | — | — | +1019.7% | +334.2% | — | — | -67.0% | -79.1% | -85.7% | -87.1% | -41.4% | -14.2% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | 50.0% | — | — | — | — | — | — | — | — | — | 100.0% | -176.8% | -191.7% | -188.5% | 24.0% | 63.5% | 86.2% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | +316.7% | -378.3% | -322.3% | +80.4% | +2709.3% | — | — | |
| Operating Margin | — | — | — | — | -63.2% | — | — | — | — | — | — | — | — | — | -23146.2% | -9498.0% | -11406.0% | -10778.7% | -3587.7% | -1794.5% | -561.0% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | -545.2% | -429.3% | -1933.2% | -643.1% | -7228.4% | — | — | |
| Net Margin | — | — | — | — | -69.1% | — | — | — | — | — | — | — | — | — | -31552.5% | -9304.0% | -11203.6% | -10479.3% | -3571.7% | -1794.1% | -561.1% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | -783.4% | -418.6% | -1896.8% | -621.9% | -7062.2% | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -25.2% | -8.9% | -4.1% | -10.0% | -10.7% | -2.5% | -7.8% | -9.0% | -13.3% | -19.7% | -14.7% | -26.1% | -34.3% | — | — | -43.9% | -31.9% | -24.0% | -30.6% | -33.6% | -22.0% |
| — | -263.7% | +47.8% | -11.2% | +19.8% | +87.5% | +46.9% | +65.7% | +61.2% | — | — | +40.6% | -7.5% | — | — | -30.7% | -45.3% | -30.9% | -444.2% | -142.8% | -33.6% | |
| ROA | -22.4% | -8.5% | -3.7% | -9.0% | -9.8% | -2.1% | -6.6% | -7.6% | -10.9% | -16.1% | -8.4% | -10.6% | -23.0% | -17.8% | -146.7% | -29.8% | -23.1% | -18.4% | -23.5% | -25.3% | -17.1% |
| — | -294.6% | +43.6% | -17.8% | +10.8% | +86.7% | +21.2% | +28.1% | +52.5% | +9.5% | +94.3% | +64.5% | +0.5% | +3.3% | -523.8% | -17.8% | -35.2% | -25.0% | -434.6% | -125.9% | -19.5% | |
| ROIC | -29.7% | -8.3% | -4.1% | -5.7% | -8.4% | -11.2% | -7.8% | -9.3% | -13.4% | -14.2% | -26.1% | — | — | — | — | -123.1% | -53.8% | -33.2% | -32.5% | -29.1% | -19.6% |
| — | +25.6% | +46.9% | +38.9% | +37.4% | +21.4% | +70.2% | — | — | — | — | — | — | — | — | -322.5% | -174.7% | -87.6% | -347.5% | -11.0% | +18.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.13 | 0.09 | 0.07 | 0.06 | 0.08 | 0.06 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +64.9% | +52.7% | +39.0% | +28.1% | +85.6% | +54.7% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 13.25 | 27.40 | 18.53 | 8.97 | 13.25 | 10.90 | 6.49 | 8.06 | 11.26 | 7.32 | 19.70 | 11.38 | 10.68 | 4.59 | 1.03 | 3.51 | 4.25 | 4.65 | 6.09 | 4.45 | 4.91 |
| — | +151.2% | +185.6% | +11.3% | +17.8% | +49.0% | -67.1% | -29.2% | +5.4% | +59.4% | +1806.9% | +224.1% | +151.4% | -1.3% | -83.0% | -21.2% | -13.5% | -19.2% | -6.6% | -4.8% | -46.1% | |
| Quick Ratio | 13.25 | 27.40 | 18.53 | 8.97 | 13.25 | 10.90 | 6.49 | 8.06 | 11.26 | 7.32 | 19.70 | 11.38 | 10.68 | 4.59 | 1.03 | 3.51 | 4.25 | 4.65 | 6.09 | 4.45 | 4.91 |
| — | +151.2% | +185.6% | +11.3% | +17.8% | +49.0% | -67.1% | -29.2% | +5.4% | +59.4% | +1806.9% | +224.1% | +151.4% | -1.3% | -83.0% | -21.2% | -13.5% | -19.2% | -6.6% | -4.8% | -46.1% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SYRE stock.
Spyre Therapeutics, Inc.'s current P/E is -34.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Spyre Therapeutics, Inc.'s business trajectory between earnings reports.